Patents by Inventor Holly Kordasiewicz

Holly Kordasiewicz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS FOR MODULATING TAU EXPRESSION
    Publication number: 20180094261
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Application
    Filed: May 11, 2017
    Publication date: April 5, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20180087052
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: May 16, 2017
    Publication date: March 29, 2018
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Modulation of huntingtin expression
    Patent number: 9683236
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: June 20, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION
    Publication number: 20170037410
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Application
    Filed: April 1, 2015
    Publication date: February 9, 2017
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Tracy Cole, Holly Kordasiewicz, Susan M. Freier, Thomas P. Condon, Edward Wancewicz, Trisha Lockhart, Timothy Vickers, Priyam Singh
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20160312217
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: January 25, 2016
    Publication date: October 27, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • COMPOSITIONS FOR MODULATING TAU EXPRESSION
    Publication number: 20160145617
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
    Type: Application
    Filed: July 21, 2014
    Publication date: May 26, 2016
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Holly Kordasiewicz, Eric E. Swayze, Susan M. Freier, Huynh-Hoa Bui
  • ANTISENSE COMPOUNDS AND USES THEREOF
    Publication number: 20160138014
    Abstract: The present disclosure provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: October 11, 2013
    Publication date: May 19, 2016
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Holly Kordasiewicz, Curt Mazur, Punit P. Seth, Eric E. Swayze
  • Modulation of huntingtin expression
    Patent number: 9273315
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: March 1, 2016
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20150159155
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Modulation of huntingtin expression
    Patent number: 8906873
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: December 9, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20120252879
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: September 10, 2010
    Publication date: October 4, 2012
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin